Alpha Tau Medical Ltd. (DRTS)
Market Cap | 152.16M |
Revenue (ttm) | n/a |
Net Income (ttm) | -29.16M |
Shares Out | 69.80M |
EPS (ttm) | -0.42 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 88,551 |
Open | 2.500 |
Previous Close | 2.540 |
Day's Range | 2.090 - 2.560 |
52-Week Range | 1.750 - 4.310 |
Beta | 0.76 |
Analysts | Strong Buy |
Price Target | 11.75 (+438.99%) |
Earnings Date | Aug 26, 2024 |
About DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multifor... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for DRTS stock is "Strong Buy." The 12-month stock price forecast is $11.75, which is an increase of 438.99% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/h/a/press7-2494996.jpg)
Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers
The pooled analysis included data from 4 i nternational clinical trials spanning a n array of hard-to-treat indications including skin, head & neck, and oral cavity.
![](https://cdn.snapi.dev/images/v1/1/q/conf18-2441458.jpg)
Alpha Tau to Present at the Jefferies Global Healthcare Conference
JERUSALEM, May 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, to...
![](https://cdn.snapi.dev/images/v1/p/f/press15-2440361.jpg)
Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Presented preclinical data demonstrating abscopal immune effect in pancreatic murine tumor models at ESTRO 2024 Congress in Glasgow -
![](https://cdn.snapi.dev/images/v1/5/t/press19-2426875.jpg)
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, an...
![](https://cdn.snapi.dev/images/v1/k/c/press4-2411893.jpg)
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow
- Initial data demonstrates significant reduction in distant pancreatic cancer tumor growth rate starting from three weeks after first tumor is treated with Alpha DaRT alone
![](https://cdn.snapi.dev/images/v1/g/w/conf19-2402688.jpg)
Alpha Tau to Participate in May Investor Conferences
JERUSALEM, May 01, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, to...
![](https://cdn.snapi.dev/images/v1/i/3/conf6-2339722.jpg)
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...
![](https://cdn.snapi.dev/images/v1/l/g/press20-2314141.jpg)
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update
- Positive interim safety and feasibility data from pancreatic cancer study in Montreal , with initial signs of potential dose response findings -
![](https://cdn.snapi.dev/images/v1/z/y/conf19-2293363.jpg)
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference
JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, t...
![](https://cdn.snapi.dev/images/v1/a/i/conf4-2203568.jpg)
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- The overview presentation will review some of the Company's recent achievements, including highly promising interim results from the Company's pancreatic cancer safety and feasibility trial as well ...
![](https://cdn.snapi.dev/images/v1/e/n/press18-2175754.jpg)
Alpha Tau to Participate in Sidoti Small-Cap Conference
JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, t...
![](https://cdn.snapi.dev/images/v1/h/v/press6-2173789.jpg)
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as no product-related Serious Adverse Events -
![](https://cdn.snapi.dev/images/v1/z/o/press14-2165145.jpg)
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer
JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K. (“...
![](https://cdn.snapi.dev/images/v1/w/g/press14-2162424.jpg)
Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety and feasibility trial in similar indication currently underwa...
![](https://cdn.snapi.dev/images/v1/q/s/press17-2154428.jpg)
Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer
BOSTON--(BUSINESS WIRE)--Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced the appointment of Kathy Berg...
![](https://cdn.snapi.dev/images/v1/b/5/press20-2127831.jpg)
Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, a...
![](https://cdn.snapi.dev/images/v1/u/t/press1-2063368.jpg)
Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical Center
JERUSALEM, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, ...
![](https://cdn.snapi.dev/images/v1/k/a/press7-2040141.jpg)
Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April –
![](https://cdn.snapi.dev/images/v1/e/p/conf3-2035715.jpg)
Alpha Tau Medical to Participate in September Investor Conferences
JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, t...
![](https://cdn.snapi.dev/images/v1/4/w/press11-2027987.jpg)
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year local recurrence-free survival rate of 77%.
![](https://cdn.snapi.dev/images/v1/r/r/conf7-2001415.jpg)
Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023
JERUSALEM, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, t...
![](https://cdn.snapi.dev/images/v1/y/c/conf20-1906175.jpg)
Alpha Tau Medical to Participate in June Investor Conferences
JERUSALEM, May 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, to...
![](https://cdn.snapi.dev/images/v1/q/x/press16-1904154.jpg)
Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update
- Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer , which began enrolling patient s in March -
![](https://cdn.snapi.dev/images/v1/0/c/press14-1896146.jpg)
Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University
-First patient treated in the feasibility and safety study of intratumoral diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of new and recurrent squamous cell carcinoma of the...
![](https://cdn.snapi.dev/images/v1/6/m/press20-1886135.jpg)
Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open
JERUSALEM, May 11, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, an...